MODIFIED PEPTIDE AND USING IT FOR CNS CANCER SCREENING AND THERAPEUTIC EFFECTIVENESS TESTS Russian patent published in 2013 - IPC C07K9/00 G01N33/531 G01N33/68 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes a chemically modified peptide that is a fragment of human protein S100β consisting of a sequence of 15 amino acids corresponding to the amino acids in position 18-32 of the amino acid sequence of protein S100β. The peptide is covalently bound to a spacer (Ahx) consisting of 2-aminoheptane acid or a similar compound, and covalently bound to the spacer by a biotin molecule (Bio). The peptide is described by general formula: A-Tyr¹-Ser²-Gly³-Arg⁴-Glu⁵-Gly⁶-Asp⁷-Lys⁸-His⁹-Lys¹⁰-Leu¹¹-Lys¹²-Lys¹³-Ser¹⁴-Glu¹⁵-E, wherein A represents Bio-Ahx, Bio-Acp, Bio or 0, and B represents 0 or -NH₂. Bio means biotin; Ahx means a residue of 2-aminoheptane acid; Acp means a residue of 6-aminocapronic acid, 0 means the absence of any amino acid. A diagnostic technique and a method for prediction of melanoma provides measuring blood natural antibodies (nAB) to the peptide according to the invention with the stages of melanoma diagnosed by the antibody concentration as compared to the reference. The clinical outcome and therapeutic effectiveness in a craniocereberal injury are predicted by measuring the nAB to the peptide according to the invention. If observing the blood nAB level in the patients lower as compared to the standard reference, the favourable clinical outcome is diagnosed, and the therapy is stated to be effective.

EFFECT: invention may be used effectively as instant diagnosing of the disturbed blood-brain barrier and monitoring of the clinical effectiveness in CCIs and some cancers.

3 cl, 9 dwg, 1 tbl, 5 ex